Mona Ashiya

General Partner atOrbiMedNew York

Mona Ashiya is a General Partner at OrbiMed. She previously worked in biotechnology equity research at J.P. Morgan.

What Mona can write

Writes checks of$1M to $30M+
Comes in atSeed, Series A, Series BCan lead the round
Ownership target7-10%At first check
Email the firm[email protected]The firm's own inbox for founders.

OrbiMed writes $1M to $30M+ checks, larger than 83% of firms in the atlas.

Bars: how many firms report each check band. Highlighted: OrbiMed.

Career

  1. Harvard Business School
  2. Global Alliance for TB Drug Development
  3. J.P. Morgan · member of biotechnology equity research team
  4. OrbiMed · General Partner
    Now

Investments named in public bios

Sierra OncologyDisc MedicineProfoundBio

Focus

biotechnologyventure capitalspecial situationslife sciences

Education

University of California at Berkeley, B.A.University of Pittsburgh, Ph.D. in Cellular, Molecular, and Developmental BiologyDana Farber Cancer Institute, post-doctoral fellow

Also at OrbiMed

Partners like Mona

At firms with a similar stage, sector and check size.

Alert me when OrbiMed is active

One email when Mona's firm raises a fund, adds a partner or shows new activity.

Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Questions

Who is Mona Ashiya?

Mona Ashiya is a General Partner at OrbiMed. She previously worked in biotechnology equity research at J.P. Morgan.

How much does Mona Ashiya invest?

Mona Ashiya invests through OrbiMed, which writes checks of $1M to $30M+ at seed, series a, series b.

How do I pitch Mona Ashiya?

Email [email protected], the firm's inbox for founders, and name Mona in the subject. A warm intro from a founder OrbiMed backed works better.

What did Mona Ashiya do before OrbiMed?

Harvard Business School; Global Alliance for TB Drug Development; member of biotechnology equity research team at J.P. Morgan.

Last updated 2026-10-15. Is this you? Ask for a correction.